Highbridge Capital Management’s AMAG Pharmaceuticals AMAG Stock Holding History

Highbridge Capital Management’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-11,842	Closed	-$157K	–	1891
2017 Q4	$157K	Buy	+11,842	New	+$179K	﹤0.01%	1538
2017 Q2	–	Sell	-88,975	Closed	-$1.76M	–	1756
2017 Q1	$2.01M	Buy	+88,975	New	+$2.13M	0.03%	447
2016 Q4	–	Sell	-111,259	Closed	-$2.73M	–	1719
2016 Q3	$2.73M	Buy	111,259 +73,498	+195%	+$1.84M	0.04%	383
2016 Q2	$903K	Sell	37,761 -245,054	-87%	-$5.62M	0.01%	644
2016 Q1	$6.62M	Sell	282,815 -152,038	-35%	-$3.61M	0.11%	213
2015 Q4	$13.1M	Buy	434,853 +81,233	+23%	+$2.62M	0.2%	136
2015 Q3	$14.1M	Buy	353,620 +32,061	+10%	+$1.99M	0.22%	128
2015 Q2	$22.2M	Buy	321,559 +99,820	+45%	+$6.28M	0.28%	91
2015 Q1	$12.1M	Buy	221,739 +97,839	+79%	+$4.66M	0.17%	167
2014 Q4	$5.28M	Buy	+123,900	New	+$4.48M	0.07%	299

Other funds holding AMAG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Highbridge Capital Management's AMAG Position: Q1 2018 in Review

Highbridge Capital Management sold out of AMAG Pharmaceuticals (AMAG) in Q1 2018, closing a stake of 11,842 shares — an estimated $157K sold.

Highbridge Capital Management first reported a position in AMAG in Q4 2014 and held it in 10 quarters. The position peaked at $22.2M in Q2 2015. 170 funds tracked by Wall St. Rank hold AMAG as of Q1 2018.

Highbridge Capital Management reported no remaining AMAG Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Highbridge Capital Management sold 11,842 AMAG Pharmaceuticals shares in Q1 2018, an estimated $157K.
Highbridge Capital Management first reported a position in AMAG Pharmaceuticals in Q4 2014 and held it in 10 quarters.
Highbridge Capital Management's AMAG Pharmaceuticals position peaked at $22.2M in Q2 2015.
170 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q1 2018.

Based on Highbridge Capital Management's 13F filing for Q1 2018, filed 15 May 2018.